Kerala Kaumudi Online
Sunday, 27 September 2020 7.09 AM IST

Russian government is seeking a partnership with India for manufacturing Sputnik V


NEW DELHI: Russian government is seeking a partnership with India for manufacturing its COVID-19 vaccine 'Sputnik V' and conducting its third clinical trial here. The matter was discussed by the national expert group on vaccine administration for Covid-19 in its last meeting held on August 22.

Sputnik V has been developed by the Gamaleya Research Institute of Epidemiology and Microbiology in collaboration with the Russian Direct Investment Fund (RDIF). The vaccine has not been tested in the third phase of trials.

There have been some doubts from some quarters regarding the limited data related to the efficacy of the vaccine.

The Russian government has reached out to the Indian government seeking collaboration for manufacturing their COVID-19 vaccine, Sputnik V, and conducting its phase 3 trial here.

The Department of Biotechnology (DBT) along with the Department of Health Research has been asked to lead and look into the matter. They (Russian government officials) have shared some information and data on Sputnik V, while more data related to the safety and efficacy of the vaccine is awaited.

When asked if the Russian government has placed any formal request for the manufacture of its Covid-19 vaccine in India, Union health secretary Rajesh Bhushan said at a press conference, "As far as Sputnik V vaccine is concerned, both India and Russia are in communication. Primary information has been shared while some detailed information is awaited."

According to sources, Russian Ambassador to India Nikolay Kudashev has approached the office of Principal Scientific Advisor K Vijay Raghavan as well as secretaries of the departments of biotechnology and health research in this regard.

Lorem ipsum dolor sit amet
consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
We respect your privacy. Your information is safe and will never be shared.